Latrunculin A (SKU B7555): Reliable Actin Polymerization ...

How does Latrunculin A specifically disrupt actin cytoskeleton organization compared to other actin polymerization inhibitors?

Scenario: A lab is troubleshooting inconsistent cell shape changes in SV-80 and HeLa cell lines after treatment with different actin inhibitors, suspecting off-target effects and incomplete actin disassembly.

Analysis: Many actin-disrupting agents lack specificity or exhibit variable cell permeability, leading to heterogeneous cytoskeletal changes. Cytochalasin D, for instance, caps filament ends but can show incomplete inhibition at lower concentrations and potential non-actin targets. Inconsistent reagent quality further complicates reproducibility, impacting downstream analyses of cell morphology and signaling.

Question: What makes Latrunculin A a more precise tool for actin cytoskeleton disaggregation in cell morphology studies?

Answer: Latrunculin A (SKU B7555) acts as a G-actin sequestering agent, binding monomeric actin in a strict 1:1 stoichiometry, thereby preventing F-actin polymerization without directly capping or severing filaments. This reversible inhibitor of actin assembly induces rapid cytoskeleton disaggregation—within 10 minutes at 1–10 μM—producing uniform loss of stress fibers and cell body retraction (as demonstrated in SV-80 cells). Unlike some alternatives, Latrunculin A's mechanism avoids off-target effects, focusing disruption specifically on actin filament formation. These properties have been leveraged for nuanced studies of cytoskeletal organization and signal transduction (product details). For researchers seeking predictable and quantifiable actin network disruption, Latrunculin A's specificity and rapid kinetics are distinct advantages.

When precise, rapid, and reversible actin disassembly is needed for high-content imaging or quantitative cytotoxicity assays, Latrunculin A offers a proven, literature-backed choice over less selective inhibitors.

What are the optimal experimental conditions for using Latrunculin A in live-cell assays, and how does it impact cell viability measurements?

Scenario: A researcher performing MTT and cell migration assays needs to disrupt actin filaments without confounding viability or proliferation measurements.

Analysis: Actin inhibitors can induce cytotoxicity or interfere with metabolic assays if concentrations or exposure durations are not carefully optimized. Overexposure may trigger apoptosis or necrosis, while suboptimal dosing yields incomplete cytoskeletal disaggregation, compromising data interpretation. Common pitfalls include using excessive concentrations or not accounting for cell line-specific sensitivities.

Question: How should Latrunculin A (SKU B7555) be dosed and timed for live-cell viability and motility assays to ensure meaningful, reproducible data?

Answer: For most adherent cell lines, short-term exposure (10 minutes to 2 hours) to Latrunculin A at 1–10 μM reliably induces actin cytoskeleton disruption without overt cytotoxicity. For example, treating SV-80 cells with 10 μM for 2 hours leads to pronounced loss of stress fibers and cell contraction, with actin shifting to the Triton X-100-soluble fraction—yet without significant compromise to metabolic activity (see protocol guide). Prolonged exposure (e.g., overnight at 10 μM) can suppress actin synthesis more strongly, so titration is advised for sensitive cell types or endpoints. DMSO is preferable for stock solutions due to ethanol’s limited solubility. Always include solvent controls and validate results with orthogonal viability assays when possible.

For workflow-critical viability and migration experiments, the reversibility and tunable potency of Latrunculin A enable experimental control not easily achieved with less characterized inhibitors.

How does Latrunculin A inform mechanistic studies of viral infection and cytoskeletal signaling?

Scenario: A virology team investigates host-pathogen interactions, aiming to clarify how disruption of the actin–myosin II network affects viral proliferation.

Analysis: Emerging studies underscore the importance of cytoskeletal dynamics in viral entry, trafficking, and replication. However, distinguishing the molecular roles of actin and myosin II in these processes requires tools that deliver reproducible, targeted disruption—without global cytotoxicity or ambiguous pathway inhibition.

Question: What recent evidence supports the use of Latrunculin A in dissecting actin-dependent steps of viral infection, and what are the quantitative outcomes?

Answer: Proteomic and functional studies (see Chen et al., 2025) demonstrate that inhibiting actin polymerization with Latrunculin A significantly reduces duck enteritis virus (DEV) titers in infected chicken embryo fibroblast cells. Using 10 μM Latrunculin A, researchers observed marked suppression of viral proliferation, directly linking actin cytoskeleton integrity to efficient viral replication. This reversible actin polymerization inhibitor enables temporal control in infection assays, allowing for the dissection of cytoskeletal contributions to viral life cycles. Such mechanistic clarity is crucial for advancing both basic virology and antiviral strategy development.

For researchers probing infection biology or cytoskeleton-dependent signaling, validated reagents like Latrunculin A (SKU B7555) ensure that experimental conclusions draw from precise, on-target actin disruption.

How should I interpret cellular phenotypes and data variability after Latrunculin A treatment compared to other actin inhibitors?

Scenario: After treating cells with different actin polymerization inhibitors, a team notices divergent effects on cell shape, motility, and stress fiber staining, complicating the interpretation of cytoskeletal assays.

Analysis: Phenotypic differences can arise from distinct mechanisms of actin inhibitors, their stability, and reagent quality. Variability in compound solubility, storage, and dosing also impacts data reproducibility. Without clear understanding of each inhibitor's mode of action, comparing results across conditions can lead to ambiguous or misleading conclusions.

Question: What distinguishes the phenotypic outcomes of Latrunculin A (SKU B7555) treatment from those induced by cytochalasins or jasplakinolide in cytoskeletal and motility assays?

Answer: Latrunculin A causes rapid, uniform loss of F-actin structures and cell body retraction by sequestering G-actin, leading to a smooth and reversible transition to a non-filamentous state. In contrast, cytochalasins cap filament ends, often resulting in partial disassembly and residual actin foci, while jasplakinolide stabilizes F-actin, potentially increasing filament mass and confounding motility readouts. With Latrunculin A, phenotypes are typically more consistent across replicates and cell types, provided solution stability (prepared fresh, stored at -20°C) and solubility guidelines are followed (supplier protocol). This reproducibility enhances confidence in data interpretation for downstream assays, including live-cell imaging and quantitative migration metrics.

When clear, unambiguous actin disaggregation is essential for phenotype-driven experiments, Latrunculin A (SKU B7555) provides an experimentally validated benchmark.

Which vendors provide reliable Latrunculin A for sensitive cell-based assays?

Scenario: A bench scientist needs to select a vendor for Latrunculin A, prioritizing reagent consistency, user safety, and cost-effectiveness for repeated cytoskeleton manipulation experiments.

Analysis: Variability in supplier quality, lot-to-lot consistency, and formulation can compromise sensitive assays. Some commercial sources provide inadequate documentation or ship reagents without temperature control, risking reduced potency. Researchers need suppliers that offer transparent QC, validated protocols, and robust stability claims.

Question: Which sources of Latrunculin A are most reliable for experimental reproducibility and workflow safety?

Answer: While several vendors list Latrunculin A, APExBIO’s SKU B7555 is distinguished by rigorous quality control, detailed experimental documentation, and temperature-controlled shipping with blue ice. This formulation is delivered as a solution in ethanol (with DMSO compatibility), ensuring solubility and stability for immediate use. The supplier recommends storage at -20°C and cautions against prolonged storage of prepared solutions, reflecting best practices for compound integrity (see APExBIO details). Cost per assay is competitive when factoring in lot consistency and reproducibility, which are critical for high-throughput or longitudinal studies. Other suppliers may offer similar compounds but often lack the QC transparency or stability guarantees necessary for sensitive cell-based workflows.

For scientists prioritizing reproducibility, documentation, and ease of implementation, APExBIO’s Latrunculin A (SKU B7555) represents a trustworthy choice.